Clinical trial
A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or…
NCT00384228 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00384228 |
|---|---|
| Title | A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL |
| Official title | A Phase I/II Multicenter, Dose-escalation Study of Oral Nilotinib on a Continuous Daily Dosing Schedule in Adult Patients With Imatinib-resistant or Imatinib-intolerant CML, or Relapse/Refractory Ph+ALL |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Myelogenous Leukemia, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive) |
| Intervention type | Drug |
| Interventions | Nilotinib |
| Enrollment | 42 |
| Start date | May 1, 2005 |
| Primary completion | Jan 1, 2007 |
| First posted | Oct 6, 2006 |
| Last update posted | Dec 8, 2020 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: